Valuation: Daxor Corporation

Market Cap 67.9M 59.11M 55.8M 50.7M 94.94M 6.51B 95.4M 667M 258M 3.31B 255M 249M 10.65B P/E 2026 *
-55.4x
P/E 2027 * -388x
Enterprise Value 67.9M 59.11M 55.8M 50.7M 94.94M 6.51B 95.4M 667M 258M 3.31B 255M 249M 10.65B EV / Sales 2026 *
7.3x
EV / Sales 2027 * 4.14x
Free-Float
46.7%
Yield 2026 *
-
Yield 2027 * -
1 week-0.17%
Current month+13.60%
1 month+11.27%
3 months+17.44%
6 months+3.06%
Current year-22.37%
1 week 10.56
Extreme 10.555
12.25
1 month 9.55
Extreme 9.5501
12.25
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2012
Director of Finance/CFO 69 27/09/2018
Chief Tech/Sci/R&D Officer - 04/06/2024
Director TitleAgeSince
Director/Board Member 91 31/12/1988
Chairman 56 13/02/2017
Director/Board Member 70 21/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-0.17%+0.44%+22.20% 67.9M
+0.67%+1.10%+17.25%+120.64% 15.9B
+2.31%+3.93%+54.08%+178.69% 12.9B
-0.11%-2.50%-21.95%+20.94% 8.53B
+0.97%+1.76%+30.88%+148.36% 7.75B
-2.06%-2.35%+4.07%+20.19% 6.68B
-1.44%-4.32%-26.67%-17.66% 6.75B
+0.13%+1.94%+11.00%+26.73% 4.84B
-1.27%-4.90%+1.61%+0.80% 3.85B
+0.80%+2.83% - - 3.86B
Average -0.24%-0.37%+7.86%+57.88% 7.9B
Weighted average by Cap. -0.08%-0.13%+13.84%+84.76%

Financials

2026 *2027 *
Net sales 9.3M 8.1M 7.64M 6.94M 13M 892M 13.07M 91.41M 35.31M 453M 34.93M 34.16M 1.46B 16.4M 14.28M 13.48M 12.25M 22.93M 1.57B 23.04M 161M 62.26M 800M 61.6M 60.23M 2.57B
Net income -1.2M -1.04M -986K -896K -1.68M -115M -1.69M -11.79M -4.56M -58.51M -4.51M -4.41M -188M -200K -174K -164K -149K -280K -19.17M -281K -1.97M -759K -9.75M -751K -735K -31.37M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
18/09/26 US$11.45 -1.55% 26,884
17/09/26 US$11.63 -0.73% 31,103
16/09/26 US$11.72 +5.07% 201,091
15/09/26 US$11.15 -1.03% 15,848
14/09/26 US$11.27 -1.78% 200,675
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.45USD
Average target price
20.00USD
Spread / Average Target
+74.67%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!